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I read the article entitled ‘‘B type natriuretic peptide as a
predictor of anterior wall location in patients with non-ST-
elevation myocardial infarction’’ by Ramos et al.1 in the
March 2011 issue of Clinics with great interest. Although the
finding is instructive, I think it would be more informative if
several factors were also considered:
First, renal function was not evaluated in Ramos et al. ’s
population. B-type natriuretic peptide (BNP) is a small
polypeptide with a plasma half life of 20–30 minutes that
reflects the stress sustained by the left ventricle (LV) and
that correlates well with the LV filling pressure and the
heart failure status.2,3 Several important studies have
elucidated the fact that this miraculous myocardial stress
marker can be affected by chronic kidney disease (CKD). In
the PRIDE (PRoBNP Investigation of Dyspnea in the
Emergency department) study, Anwaruddin et al. discov-
ered that the N-terminal pro-BNP (NT-proBNP) level is
inversely associated with the glomerular filtration rate
(GFR) and that a higher cut-off value should be set for
patients with poorer renal function (GFR,60 ml/min).4
Takami et al. also tested this theory in a group of CKD
patients who had not undergone dialysis and found that the
BNP level was significantly increased compared with
hypertensive patients with normal renal function.5 They
also concluded that LV overload (higher end-diastolic
volume and pressure) may correlate fairly well with the
BNP level, independent of the severity of renal dysfunction.
McCullough et al. provided further convincing evidence of
the graded relationship between BNP cut-off values and the
GFR, further supporting the view that the interpretation of
BNP levels should build upon the differential range of renal
function.6 Theories concerning the elevation of BNP in CKD
patients include poor tolerance of fluid loading and
resultant subclinical volume overload in early CKD stages,
a higher degree of LV hypertrophy and dysfunction in
advanced CKD stages, and decreased clearance of biomar-
kers as renal function deteriorates.6,7 Given this under-
standing, it is prudent to include renal function, specifically
creatinine data, in the assessment of the impact and
predictive power of the BNP level.
In addition, age by itself may also influence the BNP
level. Fabbian et al. recently performed an elegant study
to investigate the confounding factors in decoding the NT-
proBNP level in elderly patients. They discovered that in a
medium-sized geriatric population, with a mean age of 80
years old, elevated NT-proBNP levels were associated
with lower hemoglobin levels, more atrial fibrillation and
less severe pulmonary disease and were significantly
influenced by the CKD stage.8 These results are indicative
of the more complex situation that we might face with the
elderly population, which is representing an increasing
proportion of our society as time passes. In conclusion,
considering the various obstacles that may hinder the
elucidation of the relationship between the BNP level and
patient-level outcomes, it is of vital importance that we
gather other relevant information needed to determine the
truth.
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